Imiquimod in the treatment of eyelid basal cell carcinoma.
OBJECTIVE
To assess the efficacy and safety of topical imiquimod 5% cream in the treatment of eyelid basal cell carcinoma.


METHODS
Four patients with eyelid basal cell carcinoma were treated with imiquimod once daily, 5 days per week, for 6 weeks. Tissue biopsy was taken and clinical examination with slit-lamp microscopy was performed at the beginning of the study and after a follow-up of 12 weeks. Photographic follow-up was performed from the baseline visit to 6, 12 and 26 weeks.


RESULTS
In the 12-week follow-up after imiquimod treatment, histopathological tissue sample analysis showed no signs of basal cell carcinoma in any of the patients.


CONCLUSIONS
The results indicate that 5% imiquimod cream with topical administration may represent a new therapy option for eyelid basal cell carcinoma.
Leppälä
Jari
J
Department of Ophthalmology, North Karelia Central Hospital, Joensuu, Finland. jari.leppala@kuh.fi
Kaarniranta
Kai
K
Uusitalo
Hannu
H
Kontkanen
Matti
M
D000287:Administration, Topical; D000368:Aged; D000369:Aged, 80 and over; D000634:Aminoquinolines / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000188:drug therapy* / Q000473:pathology; D005142:Eyelid Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D000077271:Imiquimod; D008297:Male; D009824:Ointments; D016896:Treatment Outcome
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D009824:Ointments; D000077271:Imiquimod